ADTKD-SEC61A1 (Autosomal Dominant Tubulointerstitial Kidney Disease, SEC61A1-related): A Patient Guide
At a Glance
ADTKD-SEC61A1 is a rare inherited kidney disease caused by a SEC61A1 gene change. It can gradually reduce kidney function and affect blood counts and growth, so lifelong monitoring and supportive care are important; transplantation can treat kidney failure without recurrence in the new kidney.
ADTKD-SEC61A1 is an ultra-rare genetic condition that affects how the kidneys and other systems in the body function over time. Formerly known as ADTKD-6, this condition is part of a group of disorders called Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD). This guide is primarily written for families of children, but ADTKD-SEC61A1 can present at any age, and the information applies to adult patients as well. Because it is so rare—with only a small number of published cases (around 15 to 20 as of recent reviews) described in the medical literature—the journey to a diagnosis often involves searching for answers to a complex puzzle of symptoms [1]. Finding the specific genetic cause in the SEC61A1 gene provides a crucial roadmap, allowing your medical team to move from uncertainty toward a targeted plan for monitoring and support [2].
At its core, this condition involves a genetic change in the instructions for a cellular structure called the translocon. Experimental studies suggest this structure acts like a doorway involved in moving proteins, such as renin, and balancing calcium within the cell’s factory [3]. When this doorway is altered, it can lead to a gradual decline in kidney function. This decline is often characterized by a “bland” urine profile, meaning there is little to no protein or blood lost in the urine early on [1]. Because the SEC61A1 gene is active throughout the body, the condition is systemic and may also involve low red blood cell counts (anemia), low white blood cell counts (neutropenia), and challenges with physical growth [4].
Managing ADTKD-SEC61A1 is a process of lifelong, proactive partnership with specialists. While there is currently no specific cure that repairs the genetic mutation, supportive care helps manage complications and protect health [5]. This includes vigilant monitoring of blood counts to quickly treat potential infections, managing blood pressure and electrolyte balance, and supporting healthy development. The pace of the disease varies, and your medical team will tailor their approach to your unique needs at every stage [2].
Looking toward the future, if the kidneys eventually reach a point where they can no longer function, kidney transplantation is a well-established solution [6]. One of the most reassuring aspects is that the genetic kidney disease does not recur in a transplanted kidney [7]. However, transplantation involves major surgery, lifelong immunosuppression, and continued monitoring, as extra-renal issues like anemia or neutropenia may persist. While the rarity of this diagnosis can feel isolating, it also places your family at the forefront of medical understanding, supported by a clear path for proactive, long-term care.
In this guide
5 chapters
Understanding ADTKD-SEC61A1 (ADTKD-6)
Learn what ADTKD-SEC61A1 (ADTKD-6) means, how SEC61A1 mutations affect kidney function, and which blood, growth, hormone, and neurologic features may occur.
Symptoms and Disease Presentation of ADTKD-SEC61A1
Learn how ADTKD-SEC61A1 affects kidney function, blood counts, growth, and development, plus infection risks from neutropenia and when to seek urgent care.
Diagnosis and Genetics of ADTKD-SEC61A1
Learn how ADTKD-SEC61A1 is diagnosed through genetic testing, why kidney biopsy may be nonspecific, and what pathogenic, VUS, and de novo results mean for care.
Management and Treatment Strategy for ADTKD-SEC61A1
Learn how ADTKD-SEC61A1 treatment supports kidney health, electrolyte balance, medication safety, blood-count planning, and future dialysis or transplant care.
Monitoring, Progression, and Transplantation in ADTKD-SEC61A1
Learn how ADTKD-SEC61A1 is monitored, how kidney function may progress, when transplant evaluation begins, and why the disease does not recur in a new kidney.
Common questions in this guide
What is ADTKD-SEC61A1 and what causes it?
What kidney and whole-body changes can ADTKD-SEC61A1 cause?
How is ADTKD-SEC61A1 managed over time?
Will ADTKD-SEC61A1 come back after a kidney transplant?
Which specialists may be part of care for ADTKD-SEC61A1?
Should family members be tested for the SEC61A1 gene change?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on tubulointerstitial kidney disease, autosomal dominant 6.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given the rarity of this condition, how can we ensure our care is coordinated between the kidney team and other specialists like hematology?
- 2.What specific signs of 'bland' kidney disease should we be monitoring in routine blood and urine tests?
- 3.How does the knowledge of the SEC61A1 mutation change the way we monitor growth and the immune system compared to other kidney patients?
- 4.If we eventually need to consider transplantation, what is the process for testing family members to ensure they don't carry the same mutation?
References
References (7)
- 1
De novo SEC61A1 mutation in congenital anemia and early-onset kidney disease: Case report and review of the literature.
Zhong L, Ding J, Ma M, et al.
Gene 2026; (993()):150106 doi:10.1016/j.gene.2026.150106.
PMID: 41850665 - 2
Hypoaldosteronism due to a novel SEC61A1 variant successfully treated with fludrocortisone.
Karpman D, Lindström ML, Möller M, et al.
Clinical kidney journal 2024; (17(8)):sfae213 doi:10.1093/ckj/sfae213.
PMID: 39135939 - 3
Phenylbutyrate rescues the transport defect of the Sec61α mutations V67G and T185A for renin.
Sicking M, Živná M, Bhadra P, et al.
Life science alliance 2022; (5(4)) doi:10.26508/lsa.202101150.
PMID: 35064074 - 4
Heterozygous Loss-of-Function SEC61A1 Mutations Cause Autosomal-Dominant Tubulo-Interstitial and Glomerulocystic Kidney Disease with Anemia.
Bolar NA, Golzio C, Živná M, et al.
American journal of human genetics 2016; (99(1)):174-87.
PMID: 27392076 - 5
Optimal patient care in advanced chronic kidney disease progressing to kidney failure.
Combe C, Alencar de Pinho N, Guedes M, et al.
Nature reviews. Nephrology 2026; (22(6)):406-421 doi:10.1038/s41581-026-01056-2.
PMID: 41667648 - 6
Renal transplant outcomes in patients with autosomal dominant tubulointerstitial kidney disease.
Cormican S, Kennedy C, Connaughton DM, et al.
Clinical transplantation 2020; (34(2)):e13783 doi:10.1111/ctr.13783.
PMID: 31958169 - 7
Diagnosis and Long-term Management of Uromodulin Kidney Disease.
Wheeler E, Thomas S
Cureus 2019; (11(3)):e4270 doi:10.7759/cureus.4270.
PMID: 31157132
This page is for informational purposes only and does not constitute medical advice about ADTKD-SEC61A1. Your nephrologist, genetics specialist, and other clinicians should interpret genetic results and plan monitoring for your family.